Lexeo Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LXEO research report →
Range $10 – $25
Price Chart
About the company
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
- CEO
- R. Nolan Townsend
- IPO
- 2023
- Employees
- 63
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on LXEO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $245.05M
- P/E
- -2.36
- Fwd P/E
- 10.51
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 1.21
- EV/EBITDA
- -1.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.29%
- ROIC
- -51.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-109,257,000
- Net Income
- $-99,961,000-1.7%
- EPS
- $-1.86+39.8%
- OCF Growth
- -21.5%
- FCF Growth
- -21.2%
- 52W High
- $10.99
- 52W Low
- $2.55
- 50D MA
- $3.25
- 200D MA
- $4.90
- Beta
- 1.65
- RSI (14)
- 47
- Avg Volume
- 1.96M
No earnings-call transcripts are available for LXEO yet.
- Free Float
- 60.7%
- Shares Outstanding
- 82.79M
- Float Shares
- 50.23M
of shares held by institutions
146 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Affinity Asset Advisors, LLC | 7.25M | ▲ 1.44M |
| Montanova Capital, LLC | 6.38M | ▲ 5.13M |
| Blackrock, Inc. | 5.97M | ▲ 234.16K |
| Ra Capital Management, L.P. | 5.00M | 0 |
| Janus Henderson Group Ltd. | 4.98M | ▼ 533.21K |
| Frazier Life Sciences Management, L.P. | 4.82M | ▲ 400.00K |
| Jpmorgan Chase & Co | 4.58M | ▲ 4.49M |
| Vestal Point Capital, LP | 4.32M | ▼ 155.00K |
| Paradigm Biocapital Advisors LP | 4.18M | ▼ 2.01M |
| Jupiter Topco LLC | 3.95M | ▲ 3.95M |
| Orbimed Advisors LLC | 3.95M | ▲ 345.40K |
| Citadel Advisors LLC | 3.90M | ▲ 63.57K |
Held by 152 ETFs
Biggest fund positions in LXEO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Tamayo Louis Edward | sell | 1,007 |
| Nov 17, 26 | Otero Jose Manuel | sell | 1,285 |
| Nov 17, 26 | Townsend Richard Nolan | sell | 3,295 |
| Nov 14, 26 | Schilke Tobin | other | 70,000 |
| Nov 14, 26 | Schilke Tobin | other | 0 |
| Sep 24, 26 | Tamayo Louis Edward | other | 54,750 |
| Sep 14, 26 | Bhalla Narinder Pal | other | 2,714 |
| Sep 24, 26 | Bhalla Narinder Pal | other | 54,750 |
| Sep 14, 26 | Otero Jose Manuel | other | 2,110 |
| Sep 24, 26 | Otero Jose Manuel | other | 54,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LXEO coverage
Recent articles, reports, and earnings notes.
No research on LXEO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LXEO report →Lexeo Therapeutics: Encouraging Gene Therapy Data, But I Want To See More
seekingalpha.com · Nov 19
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
benzinga.com · Nov 16
Lexeo Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 16
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 16
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
globenewswire.com · Nov 15
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
globenewswire.com · Nov 2
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
marketbeat.com · Oct 25
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
marketbeat.com · Oct 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.